VaultBio Signals End-to-End Ambition with Key Executive Hire

DEL MAR, CA – January 15, 2026 – Strategic advisory firm VaultBio has appointed Raffi Siyahian to its leadership team as President, Agency Services and Audience Activation, a move signaling a significant push to integrate high-level strategy with robust market execution. The appointment comes as life sciences companies increasingly demand unified partners who can guide a product from the laboratory to the patient without losing value along the way.

Siyahian, a veteran with over two decades of experience, joins VaultBio after a notable leadership tenure at ScoutLife, an agency renowned for its execution platforms in specialty care and rare disease, which merged with ConcentricLife in 2023. His arrival is poised to fortify VaultBio’s capacity to translate its strategic conclusions into tangible market impact for its pharmaceutical, biotech, and medical device clientele.

The Architect of Activation

Raffi Siyahian brings a formidable track record of building, scaling, and operating agency organizations. During his time in senior leadership at ScoutLife, he was instrumental in developing one of the industry's most recognized execution platforms, particularly within the complex and highly specialized fields of specialty care and rare disease. His career also includes senior strategy roles at the global powerhouse McCann Erickson Healthcare Worldwide, giving him a deep understanding of both strategic imperatives and executional excellence.

In his new role, Siyahian is tasked with a critical mandate: to scale and operationalize VaultBio’s Agency Services and Audience Activation capabilities. This involves defining the operating model, expanding the firm's executional offerings, and instilling a rigorous discipline in delivery. His primary objective is to ensure that the strategic insights developed by VaultBio's advisory teams are not just theoretical but can withstand the pressures and complexities of real-world market conditions.

“What drew me to VaultBio is the clarity of how the work fits together,” Siyahian stated in the announcement. “VaultBio does the heavy lifting upstream. My role is to continue to enhance the teams and systems that take that work into the market and make it function and endure in practice, with the goal of serving to better the lives of our clients’ patients and communities.”

Bridging the Molecule-to-Market Gap

VaultBio has carved out a niche as a strategic advisory firm that supports clients from “molecule through market.” Its work focuses on uncovering overlooked value and shaping the critical decisions that define a product's trajectory. However, the firm recognizes that even the most brilliant strategy is ineffective if it falters during implementation. The Agency Services and Audience Activation division is the bridge that connects this upstream strategic work to downstream market reality.

These services are responsible for translating strategic directives into concrete actions, including medical and promotional communications, omnichannel engagement campaigns, and brand activations tailored for healthcare professionals (HCPs), patients, and consumers. The appointment of Siyahian is a direct investment in strengthening this bridge.

“VaultBio’s strength is its ability to uncover value early and shape the decisions that matter most,” said Joe Young, CEO of VaultBio. “Agency Services and Audience Activation are how that work shows up in the market. Raffi brings the leadership needed to amplify that capability and grow it without compromising quality.”

This move reflects a growing sentiment among clients who are looking for more than fragmented support. “Our clients want value identified early and carried through delivery without erosion along the way,” Young added. “Raffi’s appointment strengthens our ability to meet that expectation at scale.”

Navigating a Converging Industry Landscape

VaultBio’s strategic expansion is not happening in a vacuum. It mirrors a broader evolution within the life sciences services industry, where the traditional lines between consulting, marketing, and communications are rapidly blurring. Companies are increasingly seeking end-to-end partners who can provide a seamless continuum of support, from clinical development and regulatory strategy to commercial launch and lifecycle management.

This trend is fueled by several market pressures. Regulatory shifts, such as the Inflation Reduction Act (IRA) in the United States, are putting immense pressure on pricing and portfolio optimization, making successful and efficient product launches more critical than ever. In this environment, a disjointed approach between strategy and execution can lead to costly delays and missed opportunities. Large, integrated players like IQVIA and Syneos Health have built their models on this “lab-to-life” premise, combining data, clinical trial services, and commercialization expertise under one roof.

VaultBio's appointment of Siyahian is a clear strategic play to compete more effectively in this converged landscape. By bringing in a leader known for building powerful execution engines, the firm is aiming to offer a more holistic and compelling value proposition: the deep, bespoke strategic thinking of a boutique advisory firm combined with the executional might of a full-service agency.

The Future of Engagement: Data, Digital, and Delivery

The challenge for life sciences companies today extends beyond simply getting a product to market; it involves engaging with a diverse set of stakeholders in a crowded and fragmented digital ecosystem. The industry is pivoting from a product-centric to a customer-centric model, where success depends on creating personalized, meaningful interactions with both HCPs and patients.

This requires a sophisticated omnichannel approach, where data and analytics inform every touchpoint. Siyahian’s mandate will inevitably involve enhancing VaultBio’s ability to execute these complex, data-driven campaigns. His background in specialty care and rare diseases is particularly relevant, as these therapeutic areas often involve small, hard-to-reach patient populations and highly specialized physician communities, demanding a nuanced and precise engagement strategy.

The integration of strategy and execution is essential for delivering the consistent, compelling messaging required by modern Integrated Marketing Communications (IMC). As the industry continues to harness the power of AI, machine learning, and advanced analytics to accelerate drug discovery and optimize commercial strategies, the need for leaders who can connect these technological capabilities to practical market activation will only grow, solidifying the importance of roles designed to bridge the strategic-executional divide.